Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $7.00.

A number of analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $6.00 price target (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th.

Institutional Trading of Precigen

A number of institutional investors have recently modified their holdings of PGEN. ProShare Advisors LLC increased its stake in Precigen by 26.6% in the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock valued at $58,000 after acquiring an additional 10,900 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Precigen by 8.9% in the 4th quarter. Cetera Investment Advisers now owns 283,562 shares of the biotechnology company's stock valued at $318,000 after purchasing an additional 23,250 shares in the last quarter. Cary Street Partners Financial LLC acquired a new stake in shares of Precigen in the 4th quarter valued at $98,000. Bank of America Corp DE increased its stake in shares of Precigen by 11.6% in the 4th quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company's stock valued at $232,000 after purchasing an additional 21,626 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Precigen during the 4th quarter worth $27,000. 33.51% of the stock is currently owned by institutional investors.

Precigen Stock Performance

PGEN traded down $0.02 on Friday, hitting $1.96. 2,414,131 shares of the company were exchanged, compared to its average volume of 1,533,161. The stock's fifty day moving average is $1.18 and its 200-day moving average is $1.04. Precigen has a 12 month low of $0.65 and a 12 month high of $2.10. The company has a market cap of $574.03 million, a PE ratio of -3.56 and a beta of 1.66.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.